Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Gian Marco FranceschiniOrsetta QuainiKei MizunoFrancesco OrlandoYari CianiSheng Yu KuMichael SigourosEmily RothmannAlicia AlonsoMatteo BenelliCaterina NardellaJoonghoon AuhDory FreemanBrian HanrattyMohamed AdilOlivier ElementoScott T TagawaFelix Y FengOrazio CaffoConsuelo ButtiglieroUmberto BassoPeter S NelsonEva CoreyMichael C HaffnerGerhardt AttardAna M AparicioFrancesca DemichelisHimisha BeltranPublished in: Cancer discovery (2024)
Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation of a plasma cell-free DNA targeted methylation panel that can quantify tumor fraction and identify patients with neuroendocrine prostate cancer noninvasively. This article is featured in Selected Articles from This Issue, p. 384.